Kelonia Therapeutics Reports Promising Phase 1 Results for KLN-1010 CAR-T Therapy at ASCO 2026
Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Businesswire
Image: Businesswire
Kelonia Therapeutics presented encouraging Phase 1 data for KLN-1010, an in vivo CAR-T therapy for relapsed and refractory multiple myeloma, at the 2026 ASCO Annual Meeting. The study reported a 100% overall response rate and favorable safety profile, with patients showing sustained responses beyond 9 months.
- 01KLN-1010 achieved a 100% overall response rate (ORR) with all evaluable patients showing minimal residual disease (MRD)-negative results after one month.
- 02The first patient treated remains in ongoing MRD-negative response for over 10 months.
- 03Cytokine release syndrome (CRS) was observed in 16 of 18 patients, all classified as Grade 1-2, indicating a favorable safety profile.
- 04The study demonstrated robust CAR-T cell generation and persistence without the need for lymphodepleting chemotherapy, which is typically required in traditional CAR-T therapies.
- 05Kelonia's in vivo gene therapy approach aims to democratize access to CAR-T treatments, potentially reducing wait times and eliminating preconditioning chemotherapy.
Advertisement
In-Article Ad
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Kelonia Therapeutics, Inc. reported updated results from its Phase 1 inMMyCAR study of KLN-1010, an investigational in vivo CAR-T therapy for relapsed and refractory multiple myeloma (RRMM). The study involved 18 patients, with the latest data showing a 100% overall response rate (ORR) and all evaluable patients achieving minimal residual disease (MRD)-negative status one month post-treatment. Notably, the first patient treated remains in an ongoing MRD-negative response for over 10 months. The therapy demonstrated a favorable safety profile, with 16 out of 18 patients experiencing cytokine release syndrome (CRS) classified as Grade 1-2. The study also highlighted the robust generation and persistence of CAR-T cells without the need for lymphodepleting chemotherapy, which is a common requirement in traditional CAR-T therapies. Kelonia's innovative approach aims to enhance patient access to CAR-T treatments by minimizing treatment delays and eliminating the need for preparative chemotherapy. The ongoing trial is part of a broader effort to provide effective therapies for patients with complex hematologic malignancies.
Advertisement
In-Article Ad
The promising results from KLN-1010 could significantly improve treatment options for patients with relapsed and refractory multiple myeloma, a condition with limited effective therapies.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of KLN-1010 for multiple myeloma treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.